Endocrinology, Vol 127, 2418-2422, Copyright © 1990 by Endocrine Society

ARTICLES

Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites

H Tillil, BH Frank, AH Pekar, C Broelsch, AH Rubenstein and KS Polonsky
Department of Medicine, University of Chicago, Pritzker School of Medicine, Illinois 60637.

Since circulating proinsulin has been suggested to be important in the pathogenesis of noninsulin-dependent diabetes, and biosynthetic human proinsulin (HPI) may have a therapeutic role in patients with diabetes mellitus, the biological activity of proinsulin metabolites is of potential significance. Moreover, recent studies have suggested that the majority of circulating proinsulin immunoreactivity consists of metabolites. We, therefore, compared the blood glucose-lowering ability and MCR of the two proinsulin metabolites des-(31,32)HPI and des- (64,65)HPI with intact HPI in seven anesthetized dogs after an overnight fast. Intravenous bolus injections of 12.5 micrograms HPI/kg BW and equimolar amounts of des-(31,32)HPI and des-(64,65)HPI were given on three separate occasions. In addition to blood glucose, des- (31,33)HPI, des-(64,65)HPI, and HPI were measured using an insulin RIA and peptide-specific standard curves. Kinetic parameters were derived by fitting two exponentials to the respective decay curves. The MCR of HPI (3.3 +/- 0.1 ml/kg.min) was significantly lower (P less than 0.05) than that of des-(64,65)HPI (6.4 +/- 0.6 ml/kg.min), but was not significantly different from that of des-(31,32)HPI (3.8 +/- 0.4 ml/kg.min). The MCR of biosynthetic insulin (17.2 +/- 1.8 ml/kg.min), as measured in three of the dogs, was higher than that of HPI or the two metabolites. The blood glucose-lowering ability (defined as nadir glucose/fasting glucose, expressed as a percentage) of des-(64,65)HPI (49.3 +/- 5.0%) was significantly greater (P less than 0.05) than that of intact HPI (87 +/- 2.2%), and the glucose-lowering ability of des- (31,32)HPI (75.2 +/- 3.8%) was intermediate. In conclusion, HPI metabolites are more biologically active than intact HPI. The extent of in vivo conversion of proinsulin to metabolites may enhance the biological activity of proinsulin and, thus, have physiological, pathophysiological, and therapeutic significance.

This article has been cited by other articles:

				Z.-l. Wan, K. Huang, S.-Q. Hu, J. Whittaker, and M. A. Weiss The Structure of a Mutant Insulin Uncouples Receptor Binding from Protein Allostery: AN ELECTROSTATIC BLOCK TO THE TR TRANSITION J. Biol. Chem., July 25, 2008; 283(30): 21198 - 21210. [Abstract] [Full Text] [PDF]

				J. A. Westgate, R. S. Lindsay, J. Beattie, N. S. Pattison, G. Gamble, L. F.J. Mildenhall, B. H. Breier, and F. D. Johnstone Hyperinsulinemia in Cord Blood in Mothers With Type 2 Diabetes and Gestational Diabetes Mellitus in New Zealand. Diabetes Care, June 1, 2006; 29(6): 1345 - 1350. [Abstract] [Full Text] [PDF]

				S. A. Smith, L. E. Porter, N. Biswas, and M. I. Freed Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6048 - 6053. [Abstract] [Full Text] [PDF]

				R. S. Lindsay, J. D. Walker, I. Halsall, C. N. Hales, A. A. Calder, B. A. Hamilton, and F. D. Johnstone Insulin and Insulin Propeptides at Birth in Offspring of Diabetic Mothers J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1664 - 1671. [Abstract] [Full Text] [PDF]

				P. Houssa, B. Dinesen, M. Deberg, B. H. Frank, C. Van Schravendijk, F. Sodoyez-Goffaux, and J.-C. Sodoyez First direct assay for intact human proinsulin Clin. Chem., July 1, 1998; 44(7): 1514 - 1519. [Abstract] [Full Text] [PDF]